Predicting GLP-1 Discontinuation From Pharmacy Claims
Published: | Updated:
|Articles|July 1, 2001
Supplements and Featured Publications
- New Developments in the Treatment of Irritable Bowel Syndrome
- Volume 7
- Issue 8 Suppl
Drug Therapy Options for Patients with Irritable Bowel Syndrome
Author(s)Nicholas J. Talley, MD, PhD
Advertisement
Articles in this issue
about 25 years ago
Participating Facultyabout 25 years ago
Introductionabout 25 years ago
Defining and Diagnosing Irritable Bowel Syndromeabout 25 years ago
The Role of Serotonin in the Pathophysiology of Irritable Bowel Syndromeabout 25 years ago
Irritable Bowel Syndrome: Toward a Cost-Effective Management Approachabout 25 years ago
Continuing Medical Education Quizabout 25 years ago
Selected AbstractsAdvertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
5 Things to Know About the FDA's Peptide Reversal
2
Moderna, Merck mRNA Cancer Vaccine Succeeds in Late-Stage Trial
3
FDA Approves First Orexin Agonist for Narcolepsy Type 1
4
Ochsner Health, Paradigm Health Partnership Expands Clinical Trial Access Across the Gulf South
5